Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

Main Article Content

Stephan Weidinger
Jonathan Silverberg
Darryl Toth
Thomas Bieber
Andrew Alexis
Boni Elewski
Andrew Pink
DirkJan Hignen

Keywords

Atopic Dermatitis, Tralokinumab, Topical Cortocisteroid, Efficacy, Safety

Abstract

Abstract not available.

References

1. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

2. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.

3. Dalgard FJ et al. J Invest Dermatol 2015; 135: 984–991.

4. Bieber T. Allergy 2020; 75: 54–62.

5. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489.

6. Popovic B et al. J Mol Biol 2017; 429: 208–219.

7. Silverberg JI et al. Br J Dermatol 2020; in press.

Most read articles by the same author(s)

1 2 3 > >>